Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database
Authors' conclusion
Among patients with RA, individuals using JAKIs had a significantly higher risk of overall cardiovascular events than TNFIs users, which was attributed to the difference in the risk between JAKIs and TNFIs versus MTX.
Study context
- Population
- Japanese patients with rheumatoid arthritis (RA) aged ≥18 years (ICD-10 M05 or M06), new users of JAKi, biological disease-modifying antirheumatic drugs (bDMARDs) or methotrexate (MTX) between July 2013 and July 2020
- Participants
- 53,448 patients
- Exposure
- JAKi vs bDMARDs and MTX
- Outcome
- Overall cardiovascular events:
- VTE
- Arterial thrombosis
- Acute MI
- Stroke
Methodological detailsJapanese health insurance claims database, new users, time-dependent Cox regression adjusted for baseline characteristics
- Japanese health insurance claims database
- New users
- Time-dependent Cox regression adjusted for baseline characteristics
Main finding
As reported in the abstract
Overall cardiovascular events, incidence rate (IR)/1000 patient-years
Adjusted hazard ratio (95% CI)
JAKIsvs TNFIs without MTX
1.7(1.1–2.5)
JAKIsvs TNFIs with MTX
1.7(1.1–2.7)
Observational data: associations, not effects.
Original publication
Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database. RMD Open. Published 17 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →